CRPHAGE
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 Jan 2024)
What this means for you
This application is over — abandoned 08 Jan 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97169063
- Mark type
- Stylized text
- Filed
- 13 Dec 2021
- Published for opposition
- 11 Apr 2023
- Abandoned
- 08 Jan 2024
- Attorney of record
- Chelsea E. Carbone
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for targeting and destroying bacteria; pharmaceutical preparations for the treatment of antibiotic-resistant bacterial infections and microbiome-related disorders; pharmaceutical preparations for use in the field of engineered bacteriophage; pharmaceuticals designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, cancer, autoimmune and inflammatory diseases namely, transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases
Owner
- Locus Biosciences, Inc., Morrisville, NC, US
- Locus Biosciences, Inc., Morrisville, NC, US
Prosecution history
- 08 Jan 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 08 Jan 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 06 Jun 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Apr 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Apr 2023 — PUBLISHED FOR OPPOSITION
- 22 Mar 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Mar 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Mar 2023 — EXAMINER'S AMENDMENT ENTERED
- 07 Mar 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 07 Mar 2023 — EXAMINERS AMENDMENT E-MAILED
- 07 Mar 2023 — EXAMINERS AMENDMENT -WRITTEN
- 21 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Sept 2022 — NON-FINAL ACTION E-MAILED
- 21 Sept 2022 — NON-FINAL ACTION WRITTEN
- 20 Sept 2022 — ASSIGNED TO EXAMINER